Evidence map›Paper›PMID 33159025›Full record

ArticleAsian journal of andrology

TGF-β1-regulated miR-3691-3p targets

Yue-Mei Hu, Xiao-Li Lou, Bao-Zhu Liu, Li Sun, Shan Wan, Lei Wu, Xin Zhao, Qing Zhou, Mao-Min Sun, Kun Tao and 2 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yue-Mei HuDepartment of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
Xiao-Li LouDepartment of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
Bao-Zhu LiuCollaborative Innovation Center of Clinical Immunology between Soochow University and Sihong People's Hospital, Sihong 223900, China.
Li SunLaboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China.
Shan WanDepartment of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
Lei WuLaboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China.
Xin ZhaoDepartment of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
Qing ZhouDepartment of Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Mao-Min SunLaboratory Animal Research Center, Soochow University School of Medicine, Suzhou 215123, China.
Kun TaoDepartment of Pathology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China.
Yong-Sheng ZhangDepartment of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
Shou-Li WangDepartment of Pathology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou 215123, China.
Soochow University · CNTongren Hospital · CNFirst Affiliated Hospital of Soochow University · CNShanghai Jiao Tong University · CNZhongshan People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transforming growth factor-β1 (TGF-β1) acts as a tumor promoter in advanced prostate cancer (PCa). We speculated that microRNAs (miRNAs) that are inhibited by TGF-β1 might exert anti-tumor effects. To assess this, we identified several miRNAs downregulated by TGF-β1 in PCa cell lines and selected miR-3691-3p for detailed analysis as a candidate anti-oncogene miRNA. miR-3691-3p was expressed at significantly lower levels in human PCa tissue compared with paired benign prostatic hyperplasia tissue, and its expression level correlated inversely with aggressive clinical pathological features. Overexpression of miR-3691-3p in PCa cell lines inhibited proliferation, migration, and invasion, and promoted apoptosis. The miR-3691-3p target genes E2F transcription factor 3 (E2F3) and PR domain containing 1, with ZNF domain (PRDM1) were upregulated in miR-3691-3p-overexpressing PCa cells, and silencing of E2F3 or PRDM1 suppressed PCa cell proliferation, migration, and invasion. Treatment of mice bearing PCa xenografts with a miR-3691-3p agomir inhibited tumor growth and promoted tumor cell apoptosis. Consistent with the negative regulation of E2F3 and PRDM1 by miR-3691-3p, both proteins were overexpressed in clinical PCa specimens compared with noncancerous prostate tissue. Our results indicate that TGF-β1-regulated miR-3691-3p acts as an anti-oncogene in PCa by downregulating E2F3 and PRDM1. These results provide novel insights into the mechanisms by which TGF-β1 contributes to the progression of PCa.

Indexed as

AgedAnimalsApoptosisCell Line, TumorCell MovementCell ProliferationE2F3 Transcription FactorHumansMaleMiceMice, NudeMicroRNAsNeoplasm TransplantationPC-3 CellsPositive Regulatory Domain I-Binding Factor 1Prostatic NeoplasmsE2F3 protein, humanE2F3 Transcription FactorMicroRNAsMIRN3691 microRNA, humanPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanTGFB1 protein, humanTransforming Growth Factor beta1E2F transcription factor 3; miR-3691-3p; PR domain containing 1with ZNF domain; prostate cancer; transforming growth factor-β1

Identifiers

PMID33159025
PMCPMC7991816
OpenAlexW3095877110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.